<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2575">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04376814</url>
  </required_header>
  <id_info>
    <org_study_id>IR.BMSU.REC.1399.017</org_study_id>
    <nct_id>NCT04376814</nct_id>
  </id_info>
  <brief_title>Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19</brief_title>
  <official_title>The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baqiyatallah Medical Sciences University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baqiyatallah Medical Sciences University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized clinical trial study. The number of 40 COVID-19
      patients with moderate severity will be admitted in progressive care units (PCUs) and
      intensive care units (ICUs) enrolled in the study. The sampling will be purposive and based
      on the same independent variables, including age, gender, past medical histories, and the
      situation of the patient at the admission day, and ventilator support. The patients will be
      allocated into two groups with different regimens. Group &quot;A&quot; (regimen A)will be defined as
      Favipiravir 1600 mg a first dose and 600 mg in 3 divided doses daily plus 400 mg in 2 divided
      doses of Hydroxychloroquine every day. The group &quot;B&quot; (regimen B) will be contained 400 mg of
      Lopinavir/Ritonavirin 2 divided doses plus the first dose (400 mg) of Hydroxychloroquine.
      Hydroxychloroquine will not be used for adverse drug reactions. The regimen remained at least
      7 up to 10 days.

      Data will be analyzed using statistical package for social sciences (SPSS) version 18 (SPSS
      Inc. Chicago, IL, USA) for windows. The variables will be compared using independent and
      paired T-test for normally distributed variables and Wilcoxon, Chi-square for non-normal
      distributed variables. The Kaplan Meier test will be used for survival analysis and the
      one-sample Kolmogorov-Smirnov test for the evaluation of distributions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2020</start_date>
  <completion_date type="Actual">May 25, 2020</completion_date>
  <primary_completion_date type="Actual">April 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>In-hospital mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>long of hospitalization</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>long of hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Treatment Response (Blood cell count)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Laboratory Treatment Response; return of blood cell count to normal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Treatment Response (CRP )</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Laboratory Treatment Response; return of CRP values to normal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>shortness of breath based on symptoms of Dyspnea and questioning the patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen saturation without supplemental oxygen.</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Oxygen saturation without supplemental oxygen. Measurement will be done after discontinuation of oxygen therapy for 5 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen therapy</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Oxygen therapy maximum flow during the day (lit/min)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>COVID-19</condition>
  <condition>Favipiravir</condition>
  <condition>Kaletra</condition>
  <condition>Hydroxychloroquine</condition>
  <condition>Lopinavir/Ritonavir</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days, plus 200mg of Hydroxychloroquine two times per day will be given to patients for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, Patients will be given a stat dose of 400mg Hydroxychloroquine tablets plus 200/50 mg of Lopinavir/Ritonavirtwo times per day for seven days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days</description>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir / Ritonavir</intervention_name>
    <description>Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Kaletra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COVID-19 based on either ground glass appearance in chest CT scan or
             positive RT-PCR test for COVID-19

          -  Requiring hospitalization

          -  Patient's age between 16 and 100 years

          -  Signed informed consent form

        Exclusion Criteria:

          -  Receiving other antiviral medications such as (Kaletra, Ribavirin, Oseltamivir)

          -  Chronic liver or renal failure

          -  HIV; GI bleeding

          -  Pregnancy

          -  Lactation

          -  QT interval &gt; 500 ms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mohammad Sadegh Bagheri Baghdasht</name>
      <address>
        <city>Tehran</city>
        <zip>0</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baqiyatallah Medical Sciences University</investigator_affiliation>
    <investigator_full_name>Mohammad Sadegh Bagheri Baghdasht</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

